Rafferty Asset Management LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 12.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 166,423 shares of the company's stock after purchasing an additional 18,598 shares during the quarter. Rafferty Asset Management LLC's holdings in Kenvue were worth $3,553,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at $29,000. SRS Capital Advisors Inc. raised its holdings in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Asset Planning Inc bought a new position in shares of Kenvue during the 4th quarter valued at $42,000. Finally, Clarity Asset Management Inc. bought a new position in Kenvue in the 4th quarter worth $45,000. Institutional investors own 97.64% of the company's stock.
Kenvue Stock Performance
NYSE KVUE traded up $0.26 during midday trading on Friday, hitting $23.76. The company had a trading volume of 10,164,041 shares, compared to its average volume of 16,369,512. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $45.59 billion, a price-to-earnings ratio of 44.83, a P/E/G ratio of 2.62 and a beta of 1.02. The firm has a fifty day simple moving average of $23.23 and a two-hundred day simple moving average of $22.62. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business's quarterly revenue was down 3.9% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. Kenvue's dividend payout ratio (DPR) is currently 149.09%.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Citigroup lifted their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a report on Friday, May 9th. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. UBS Group lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Finally, Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $25.33.
Read Our Latest Research Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
